I think the problem is the article detaches "Pharmacy-Benefit Managers" from Pharma costs and into "Services" as a separate category... they're definitely close

I think the problem is the article detaches "Pharmacy-Benefit Managers" from Pharma costs and into "Services" as a separate category... they're definitely closer to Pharma in terms of the structure, where that money goes is up for debate. There should probably be trade (FTC) violation of some kind from this layer of man in the middle gouging, which is on top of the higher direct prices of the medications to begin with in the US.